DDInter1508 DDInter899
Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversibly binds to P2Y12 type ADP receptors on platelets thus preventing activation of the GPIIb/IIIa receptor complex. As a result, inhibition of ADP-mediated platelet activation and aggregation occurs. Prasugrel was developed by Daiichi Sankyo Co. and is currently marketed in the United States and Canada in cooperation with Eli Lilly and Company for acute coronary syndromes planned for percutaneous coronary intervention (PCI). FDA approved in 2009.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Prasugrel {u} (Compound) binds {v} (Gene) P2RY12
Prasugrel {u} (Compound) is included by {v} (Pharmacologic Class) P2Y12 Receptor Antagonists
Prasugrel {u} (Compound) causes {v} (Side Effect) Hypersensitivity
Prasugrel {u} may cause a minor interaction that can limit clinical effects when taken with {v} Chamomile
Prasugrel {u} may cause a minor interaction that can limit clinical effects when taken with {v} Dexlansoprazole
Prasugrel {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Milnacipran
Prasugrel {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Vortioxetine
Prasugrel {u} may lead to a major life threatening interaction when taken with {v} Dipyridamole
Prasugrel {u} may lead to a major life threatening interaction when taken with {v} Dalteparin
Prasugrel {u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v} Clopidogrel
Prasugrel (Compound) binds P2RY12 (Gene)
Prasugrel (Compound) is included by P2Y12 Receptor Antagonists (Pharmacologic Class)
Prasugrel (Compound) causes Hypersensitivity (Side Effect)
Prasugrel may cause a minor interaction that can limit clinical effects when taken with Chamomile
Prasugrel may cause a minor interaction that can limit clinical effects when taken with Dexlansoprazole
Prasugrel may cause a moderate interaction that could exacerbate diseases when taken with Milnacipran
Prasugrel may cause a moderate interaction that could exacerbate diseases when taken with Vortioxetine
Prasugrel may lead to a major life threatening interaction when taken with Dipyridamole
Prasugrel may lead to a major life threatening interaction when taken with Dalteparin
Prasugrel (Compound) resembles Clopidogrel (Compound) and Prasugrel may lead to a major life threatening interaction when taken with Clopidogrel